Prescription drug · NDA
Xolremdi (Mavorixafor) NDC 83296-100
Mavorixafor 100 mg/1 · Capsule, Gelatin coated · Oral · X4 Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 83296-100-12 | 83296010012 | 120 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-12)Marketed from May 21, 2024 | |
| 83296-100-60 | 83296010060 | 60 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-60)Marketed from May 21, 2024 | |
| 83296-100-90 | 83296010090 | 90 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-90)Marketed from Nov 1, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Xolremdi
- Generic name (nonproprietary)
- mavorixafor
- Active ingredients
- Mavorixafor — 100 mg/1
- Dosage form
- Capsule, Gelatin coated
- Route
- Oral
- Labeler
- X4 Pharmaceuticals, Inc.NDC labeler code 83296
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 218709
- Marketing start
- Listing expires
- Identifiers
- Product ID 83296-100_26bdd232-8068-9080-e063-6394a90aa084SPL ID 26bdd232-8068-9080-e063-6394a90aa084SPL set ID 7f3a5ee3-ca73-4876-85a0-ed1e108a2237RxCUI 2684026, 2684032UNII 0G9LGB5O2W
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N483296010012followed by a unit qualifier and the quantityPackage 83296-0100-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. XOLREMDI is a CXC chemokine receptor 4 antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 83296-100
- What is NDC 83296-100?
- 83296-100 is the product NDC for Xolremdi (mavorixafor), Mavorixafor 100 mg/1 capsule, gelatin coated, listed with the FDA by X4 Pharmaceuticals, Inc.. It has 3 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Xolremdi (Mavorixafor).
- What is the active ingredient?
- Mavorixafor.
- Who is the labeler?
- X4 Pharmaceuticals, Inc., NDC labeler code 83296. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Xolremdi?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.